- Home
- CNFR vs MYNZ Comparison
CNFR vs MYNZ Comparison
Compare CNFR & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNFR
- MYNZ
- Stock Information
- Founded
- CNFR 2009
- MYNZ 2021
- Country
- CNFR United States
- MYNZ Germany
- Employees
- CNFR N/A
- MYNZ N/A
- Industry
- CNFR Property-Casualty Insurers
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- CNFR Finance
- MYNZ Health Care
- Exchange
- CNFR Nasdaq
- MYNZ Nasdaq
- Market Cap
- CNFR 11.4M
- MYNZ 10.5M
- IPO Year
- CNFR 2015
- MYNZ 2021
- Fundamental
- Price
- CNFR $0.43
- MYNZ $3.49
- Analyst Decision
- CNFR
- MYNZ Buy
- Analyst Count
- CNFR 0
- MYNZ 3
- Target Price
- CNFR N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- CNFR 21.5K
- MYNZ 177.3K
- Earning Date
- CNFR 05-13-2025
- MYNZ 04-15-2025
- Dividend Yield
- CNFR N/A
- MYNZ N/A
- EPS Growth
- CNFR N/A
- MYNZ N/A
- EPS
- CNFR 1.92
- MYNZ N/A
- Revenue
- CNFR $66,771,000.00
- MYNZ $893,991.00
- Revenue This Year
- CNFR $24.98
- MYNZ $20.94
- Revenue Next Year
- CNFR N/A
- MYNZ $18.01
- P/E Ratio
- CNFR $0.25
- MYNZ N/A
- Revenue Growth
- CNFR N/A
- MYNZ N/A
- 52 Week Low
- CNFR $0.45
- MYNZ $0.18
- 52 Week High
- CNFR $1.91
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- CNFR 27.57
- MYNZ 37.25
- Support Level
- CNFR $0.45
- MYNZ $2.72
- Resistance Level
- CNFR $0.68
- MYNZ $3.64
- Average True Range (ATR)
- CNFR 0.09
- MYNZ 0.52
- MACD
- CNFR -0.01
- MYNZ -0.09
- Stochastic Oscillator
- CNFR 21.32
- MYNZ 25.57
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance company engaged in the sale of property and casualty insurance products. It is engaged in three classes of insurance businesses namely commercial lines, personal lines, and wholesale agency business. Within these three businesses, the company offers various insurance products and insurance agency services. The company views the commercial and personal lines segments as underwriting business. The wholesale agency business provides non-risk bearing revenue through commissions and policy fees. Its revenues are derived from premiums earned from insurance operations.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.